ClinicalTrials.gg
RecruitingNCT06716996Updated Dec 4, 2024

RTMS for the Treatment of Post-COVID Associated Affective Symptoms

An interventional study of repeated transcranial magnetic stimulation and sham treatment in Post COVID -19 Depression, sponsored by Flurin Cathomas. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Flurin Cathomas · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in COVID-19 with a site in Switzerland — 6 open to participants now, 10 under way, 1 of them phase 3. COVID-19 · Switzerland.

Planned enrollment
36th of 49
52 · median 100
Started
2024
with 2 others
No phase
16 of 97
3 open now
Registered
94th of 97
by date

Among the 97 studies in COVID-19 with a site in Switzerland, this one is the 36th largest by planned enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2024, is one of 16 with no phase, and was the 94th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 97 studies in COVID-19 with a site in Switzerland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in COVID-19 with a site in Switzerland, or all of them as a file.
02

Study summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to major post-acute sequelae. It is estimated that over 60 million people worldwide are affected by this multisystemic condition, here referred to as post-COVID. Affective symptoms such as fatigue and depressed mood are particularly prevalent in patients with post-COVID and pose significant individual and socioeconomic burdens. This stands in stark contrast to the currently limited number of available therapeutic options. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation modality that has been demonstrated to be both safe and effective in treating various neuropsychiatric disorders, including depression. However, whether rTMS also has an effect on post-COVID associated affective symptoms remains to be elucidated.

The overall objective of this randomized, double-blinded study is twofold: First, the investigators will examine the effect of rTMS on post-COVID associated affective symptoms. 52 individuals with post-COVID will be randomized to either receive 20 sessions of rTMS or sham treatment. A detailed psychopathological assessment of the study participants will be performed before and after the completion of rTMS/sham treatment. Secondly, the investigators will perform detailed characterization of the immune system before and after rTMS/sham treatment.

The individual burden and socioeconomic costs of post-COVID-associated neuropsychiatric symptoms are enormous, however, treatment options are limited. The investigators believe that the current proposal will address this key gap in the literature by testing whether rTMS, which constitutes a novel treatment with little side effects, could alleviate these debilitating symptoms. If proven effective, this study could pave the way for a completely new way in which post-COVID conditions are treated.

03

Conditions studied

  • Post COVID -19 Depression

Keywords

  • Post COVID -19 depression
  • repeated transcranial magnetic stimulation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature
  • Age between 18-65 years
  • Proof of past COVID-19 infection by polymerase chain reaction (PCR) test or serology
  • Negative COVID- 19 PCR test at the time of inclusion
  • Affective symptoms (≥ 15 points on the Montgomery- Åsberg Depression Rating Scale) lasting for more than 12 weeks since COVID-19 infection
  • No psychiatric history prior to the COVID-19 infection
  • No major somatic comorbidities or substance use disorder

Exclusion criteria

Exclusion:

  • to the rTMS treatment e.g. cochlear implants and metallic devices close to the TMS coil, a history of strokes, head injuries or seizures/epilepsy
  • Epileptiform potentials in the electroencephalogram (EEG)
  • Previous rTMS prior to the study
  • Known severe or severe adverse reaction to rTMS
  • Women who are pregnant or breastfeeding
  • Intention to become pregnant during the course of the study
  • Psychiatric history prior to the COVID-19 infection
  • Major somatic comorbidities e.g. renal failure, hepatic dysfunction, heart failure, cardiovascular disease.
  • If the participant took antidepressants before the beginning of the study, there needs to be a . The antidepressant has to be stopped for at least 3 weeks before commencing the study.
  • The following drugs are not allowed during the study: any antidepressants, any antipsychotics, any drugs that lower the seizure threshold
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems
  • Participation in another study with treatment within the 30 days preceding and during the present study
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    rTMS

    Device: repeated transcranial magnetic stimulation

  • Placebo comparator
    sham treatment

    Device: sham treatment

Interventions

  • Devicerepeated transcranial magnetic stimulation

    20 sessions of repeated transcranial magnetic stimulation

    Also known as: rTMS

  • Devicesham treatment

    20 sessions of sham treatment

06

What researchers measure

Primary outcomes

  1. Depression severity

    Depression severity will be assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS)

    Time frame: overall up to 13 weeks depending on the amount of rTMS/sham sessions per week (including a 4 week follow up)

Secondary outcomes

  1. Individual symptom dimensions and levels of functioning/quality of life.

    Secondary outcomes will be clinical variables such as individual symptom dimensions and levels of functioning/quality of life.

    Time frame: overall up to 13 weeks depending on the amount of rTMS/sham sessions per week (including a 4 week follow up)

  2. Immune markers

    Blood-based biological variables of the immune system

    Time frame: overall up to 9 weeks depending on the amount of rTMS/sham sessions per week (biological variables will not be measured at the 4 week follow up)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Oct 2027, 35 months after the start.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 35 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 4, 2024
StartActual
Nov 14, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2028
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06716996
Lead sponsor
Flurin Cathomas
Responsible party
Flurin Cathomas (PD Dr. med., Psychiatric University Hospital, Zurich) — Sponsor-investigator
First posted
Dec 4, 2024
Start date
Nov 14, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Dec 4, 2024

Study contacts

Flurin Cathomas, PD Dr. med.
Contact
flurin.cathomas@pukzh.ch
+41583843435

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion